Chimeric antigen receptor modified T-cells for cancer treatment
T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), an...
Guardado en:
Autores principales: | Xiao Han, Yao Wang, Wei-Dong Han |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5f052065f6bb40cbb3a2e894eb1bf860 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
por: Mehran Bahraini, et al.
Publicado: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Cristina Aparicio, et al.
Publicado: (2021) -
A TCR-based Chimeric Antigen Receptor
por: Even Walseng, et al.
Publicado: (2017) -
Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression
por: Chungyong Han, et al.
Publicado: (2018) -
Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models
por: Nan Li, et al.
Publicado: (2021)